RALLYBIO CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 13.53K shares.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 561.00 shares.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 2.01K shares.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 13.53K shares 10-Q · filed 2026-08-06 | 14.09K shares derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | 561.00 shares S-4 · filed 2026-07-15 | 561.00 shares derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | 0.00 shares derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | 0.00 shares S-4/A · filed 2026-08-26 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 0.00 shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 0.00 shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-08 | 0.00 shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 0.00 shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 0.00 shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 0.00 shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-09 | 0.00 shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | 0.00 shares 10-K · filed 2024-03-12 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 0.00 shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 2.01K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-09 | 2.01K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 2.01K shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 2.01K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-10 | |
| 2021-12-31 | 0.00 shares 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |